Unique pharmacological properties of etrasimod among S1P receptor modulators
FEBS Open Bio · 2025-01 · 15 (1) · 108-121
DOI: 10.1002/2211-5463.13907 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 20.11.2024. Verfasst von Ibragim Gaidarov und 18 weiteren Autor:innen. Beteiligte Einrichtung: Beacon Discovery, San Diego, CA, USA. Hauptthemen laut MEDLINE: Sphingosine 1 Phosphate Receptor Modulators, Oxadiazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Etrasimod (ADP334) is an oral, once‐daily, selective sphingosine 1‐phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune‐mediated inflammatory diseases. Interaction between S1P and its five receptor subtypes (S1P 1 –S1P 5 ) plays a role in several physiologic systems, including the cardiovascular and immune systems. Since differences in S1PR binding and downstream intracellular signaling could contribute to distinct profiles of drug efficacy and safety, we directly compared the S1P 1–5 selectivity profile of etrasimod to three marketed S1PR modulators: fingolimod, ozanimod, and siponimod. Using both heterologous expression systems and human umbilical vein endothelial cells that spontaneously express S1P 1 , we profiled key S1P 1 downstream signaling pathways and found that etrasimod had similar potency to the other tested S1PR modulators in promoting β‐arrestin recruitment and S1P 1 internalization. However, etrasimod was notably less potent than other S1PR modulators in assays measuring S1P 1 ‐mediated G protein activation (GTPγS binding and cAMP inhibition). Relatively lower potency of etrasimod in inducing G protein signaling corresponded to significantly diminished activation of human cardiac G protein‐coupled inwardly rectifying potassium channels when compared to ozanimod. Together with pharmacokinetic properties, this pharmacologic profile of etrasimod may contribute to the positive benefit risk profile of etrasimod observed during the phase III ELEVATE UC 52 and ELEVATE UC 12 trials in patients with moderately to severely active ulcerative colitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beacon Discovery, San Diego, CA, USA.
- Arena Pharmaceuticals, San Diego, CA, USA.
- AnaBios Corporation, San Diego, CA, USA.
Förderung
- Pfizer
Zitieren
APA
Gaidarov, I., Komori, H. K., Stepniak, D. T., Bruinsma, K., Dang, H., Chen, X., Anthony, T., Gatlin, J., Karimi-Naser, L., Ton, A. T., Indersmitten, T., Miller, P. E., Ghetti, A., Abi-Gerges, N., Unett, D., Al-Shamma, H., Rabbat, C. J., Crosby, C., & Adams, J. W. (2025). Unique pharmacological properties of etrasimod among S1P receptor modulators. FEBS Open Bio, 15(1), 108-121. https://doi.org/10.1002/2211-5463.13907
Vancouver
Gaidarov I, Komori HK, Stepniak DT, Bruinsma K, Dang H, Chen X, et al. Unique pharmacological properties of etrasimod among S1P receptor modulators. FEBS Open Bio. 2025;15(1):108-121. doi:10.1002/2211-5463.13907
BibTeX
@article{Gaidarov2025,
author = {Gaidarov, Ibragim and Komori, H Kiyomi and Stepniak, Dariusz T and Bruinsma, Karin and Dang, Huong and Chen, Xiaohua and Anthony, Todd and Gatlin, Joel and Karimi-Naser, Lisa and Ton, Anh-Tuan and Indersmitten, Tim and Miller, Paul E and Ghetti, Andre and Abi-Gerges, Najah and Unett, David and Al-Shamma, Hussien and Rabbat, Christopher J and Crosby, Catherine and Adams, John W},
title = {Unique pharmacological properties of etrasimod among S1P receptor modulators},
journal = {FEBS Open Bio},
year = {2025},
volume = {15},
number = {1},
pages = {108--121},
doi = {10.1002/2211-5463.13907}
}
EUVIMED